Background: Chronic diabetes causes structural changes in the retinal capillaries of nearly all patients with a disease duration of more than 15 years. Acellular occluded vessels cause hypoxia, which stimulates sightthreatening abnormal angiogenesis in 50% of all type I diabetic patients. The mechanism by which diabetes produces acellular retinal capillaries is unknown. Materials and Methods: In this study, evidence of programmed cell death (PCD) was sought in the retinas
INTRODUCTION
Chronic diabetes ultimately produces structural changes in the retinal capillaries of nearly all patients with a disease duration of more than 15 years (1, 2) . The most characteristic structural change in both humans and rodents is a loss of capillary pericytes with a concomitant thickening of the basement membrane resulting in acellular, occluded vessels (3) . With time, the retinal hypoxia induced by these changes stimulates sightthreatening abnormal angiogenesis in perhaps glion cells (RGC) 50% of all type I diabetic patients (4). Current therapy with laser photocoagulation reduces the risk of severe visual loss by only about 50% and carries with it side effects and risks (5) .
The mechanism by which diabetes produces acellular retinal capillaries is unknown, but current hypotheses focus on direct damage to capillary cells by hyperglycemia through increased polyol pathway flux, increased de novo diacylglycerol synthesis, altered intracellular redox state, or formation of advanced glycation endproducts (6) (7) (8) (9) (10) . A common mechanistic event in the development of diabetic retinal acellular capillaries could be the induction of programmed cell death (PCD). PCD is a genetically encoded 528 Molecular Medicine, Volume 1, Number 5, July 1995 intrinsic cell suicide program whose activation is modulated by a multitude of factors that converge on common final steps to give a characteristic morphologic and biochemical phenotype (11, 12) . In this study, we demonstrate that diabetes causes PCD in p75NGFR-expressing neuroretinal cells. Nerve growth factor (NGF) treatment prevents both diabetes-induced PCD in the neuroretina and diabetes-specific pathology in the vascular retina. 
MATERIALS AND METHODS

Retinal Digest Preparations
Retinal vascular preparations were obtained from formalin-fixed eyes using a modification of the technique of Kuwabara and Cogan (14) . Samples were digested with pepsin (5% in 0.2% HCI) for 1.5 hr and trypsin (2.5% in 0.2 M Tris) for [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] min, and the isolated retinal vasculature was stained with PAS.
Quantitative Retinal Morphometry
The total number of pericytes was counted in 10 randomly selected fields of the retina using an Olympus CUE2 analyzing system. This number was normalized to the relative capillary density (pericytes/mm2 of retinal area). Acellular capillaries were quantitated by a modification of the method of Engerman and Kern (15) . A grid of 100 fields covering a total area of 6.76 mm2 of retinal area was used. Each field containing acellular capillary segments was recorded as positive, and values were normalized to mm2 of retinal area. Morphometry was performed blinded to the identity of the samples.
RESULTS
Evidence of PCD was sought in the retinae of early diabetic rats, using the ApopTag method for labeling new 3'-OH ends generated by PCD-induced DNA fragmentation (16) . Vertical cryostat sections of nondiabetic retinae stained with this procedure were essentially negative (Fig. la) (Fig. lb) . Diabetic capillary cells on flat-mount retinal digests did not exhibit significant PCD.
Since Muller cell injury has been associated with transdifferentiation into a GFAP-expressing phenotype that is normally confined to astrocytes (17) (18) (19) , GFAP immunoreactivity was determined in nondiabetic and in diabetic retinas. In nondiabetics, GFAP was only present in astrocytes ensheathing capillaries from the ganglion cell layer to the inner nuclear layer (Fig. 2a) . In diabetic retinas, GFAP immunoreactivity was strongly up-regulated and extended from the ganglion cell layer through the outer nuclear layer in a pattern consistent with the distribution of Muller cells (Fig. 2b) . This was confirmed by immunostaining with a Muller cell-specific marker, vimentin, which colocalized with GFAP ( Fig. 2 c and d) .
Muller and retinal ganglion cells (RGC) are the only cells in the neuroretina that express the low-affinity NGF receptor p75NGFR (20) . In some neuronal cells, expression of this receptor induces PCD constitutively when p75NGFR iS unbound. PCD is inhibited when p75NGFR is bound by NGF (21) . Therefore, p75NGFR expression was evaluated in normal and diabetic retinas using monoclonal antibody 192-IgG for immunohistochemistry. In nondiabetics, p75NGFR expression was weak and was localized from the ganglion cell layer to the inner nuclear layer of the retina (Fig. 3a) . Diabetes caused a strong up-regulation of p75NGFR immunoreactivity extending from the ganglion cell layer to the outer nuclear layer (Fig. 3b) . In diabetic retinas, p75NGFR colocalized with GFAP immunoreactivity (data not shown), suggesting that Muller cells were the major cell type with p75 NGFR up-regulation. This up-regulation was accompanied by an increase in available NGF binding sites, as determined by exogenous '251-NGF binding (13) (Fig. 4) NGF treatment of diabetic rats prevented PCD in both RGC and Muller cells of diabetic retina (Fig. 5) . Similarly, NGF treatment of diabetic rats prevented the development of both pericyte loss and acellular occluded capillaries as assessed by retinal digest preparations (10) . Nondiabetic animals revealed a uniform distribution of endothelial cells and pericytes, a regular capillary wall width, and only a few acellular occluded vessels. Diabetes 15 weeks in duration led to striking increases in pericyte cell loss and capillary occlusion (Fig. 6) . Quantitatively, diabetes induced a 34% loss of pericytes (1850 + 200 versus 2840 ± 50 cells/mm2 of capillary area in diabetics and nondiabetics, respectively; p < 0.001) and a nearly 8-fold increase in acellular occluded vessels compared with nondiabetics (155 + 20 versus 20 ± 2 acellular capillaries/ mm2 of retinal area in diabetics and nondiabetics, respectively; p = 0.001). In contrast, retinal vessels from NGF-treated diabetics were more similar to those of nondiabetics. The degree of pericyte loss was reduced by 76% (2600 ± 200; p = 0.001 versus untreated diabetics) and the number of acellular capillaries was reduced by 75% (40 ± 10; p < 0.001) compared with untreated diabetics.
DISCUSSION
The prevention by NGF of diabetes-induced neuroretinal programmed cell death and capillary pathology is noteworthy in several respects. First, it establishes an important link between the neuroretina and the vascular retina that has heretofore been unrecognized. Although Muller cell processes are often found in close proximity to retinal capillaries, it has not been appreciated that injury or trophic stimulation of the neuroretina could influence the retinal vessels. Earlier light and electron microscopy studies in humans and rodents showed that diabetes induces degeneration and loss of RGC and Muller cells (22, 23) . It was unclear, however, whether this degeneration occurred in parallel with but independent of diabetic vascular changes, or whether its occurrence caused, or resulted from, the vascular changes.
Second, these data provide some insight into the mechanism of diabetic neuroretinal and retinal vascular damage. They suggest that an early step in the pathogenesis of diabetic retinopathy is diabetes-induced damage and PCD in neuroretinal cells. NGF prevents PCD in these cells, just as it enhances the survival of axotomized RGC in the rat retina (24) and promotes the recovery of RGC after ischemic injury (25) . The mechanisms by which diabetes activates PCD and NGF suppresses it in these cells remains to be elucidated. The Muller cell-containing inner nuclear layer of the retina has been shown to contain vascular endothelial cell growth factor (26) , a secreted polypeptide thought to play a role in the maintenance of vascular endothelium (27, 28 
